Price T Rowe Associates Inc. MD increased its position in Clarivate Plc (NYSE:CLVT - Free Report) by 53.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,776,892 shares of the company's stock after purchasing an additional 9,691,104 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 3.91% of Clarivate worth $141,107,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in CLVT. Clarkston Capital Partners LLC raised its holdings in Clarivate by 8.1% during the 4th quarter. Clarkston Capital Partners LLC now owns 70,733,831 shares of the company's stock worth $359,328,000 after purchasing an additional 5,319,535 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Clarivate by 14.4% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 10,498,588 shares of the company's stock valued at $53,333,000 after buying an additional 1,323,329 shares during the last quarter. Perpetual Ltd raised its holdings in shares of Clarivate by 24.6% in the 4th quarter. Perpetual Ltd now owns 9,192,680 shares of the company's stock valued at $46,699,000 after purchasing an additional 1,816,936 shares during the period. Vanguard Group Inc. increased its position in Clarivate by 6.6% during the fourth quarter. Vanguard Group Inc. now owns 8,750,858 shares of the company's stock worth $44,454,000 after buying an additional 538,907 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. raised its stake in Clarivate by 33.6% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 6,492,760 shares of the company's stock valued at $32,983,000 after buying an additional 1,632,930 shares during the period. Institutional investors own 85.72% of the company's stock.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada restated a "sector perform" rating and issued a $6.00 price target on shares of Clarivate in a research report on Thursday, February 20th.
Read Our Latest Stock Analysis on CLVT
Clarivate Stock Up 1.7 %
Shares of CLVT stock traded up $0.08 during mid-day trading on Friday, reaching $4.37. 1,768,237 shares of the company's stock traded hands, compared to its average volume of 5,197,415. The company's 50-day moving average price is $3.88 and its 200-day moving average price is $4.87. Clarivate Plc has a 12 month low of $3.04 and a 12 month high of $7.30. The company has a quick ratio of 0.88, a current ratio of 0.87 and a debt-to-equity ratio of 0.88. The company has a market cap of $3.01 billion, a P/E ratio of -4.55 and a beta of 1.48.
Clarivate (NYSE:CLVT - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The business had revenue of $593.70 million during the quarter, compared to analyst estimates of $574.03 million. Clarivate had a negative net margin of 24.90% and a positive return on equity of 9.10%. During the same quarter last year, the business earned $0.14 earnings per share. Clarivate's quarterly revenue was down 4.4% compared to the same quarter last year. On average, equities analysts expect that Clarivate Plc will post 0.63 earnings per share for the current fiscal year.
Clarivate Company Profile
(
Free Report)
Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications.
Read More

Before you consider Clarivate, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clarivate wasn't on the list.
While Clarivate currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.